Acknowledgements
Cancer
CANCER
This study was an investigator-initiated trial. MSD supported the study by providing the study drugs (olaparib and pembrolizumab). This work was also supported by the Innovation Growth Engine for Planning and Demonstration of the Commercialization Promotion Agency for R&D Outcomes (NTIS-1711121252), funded by the Korean government (MSIT) (recipient: J.Y.L.); National Medical Research Council Singapore Clinician Scientist Award Senior Investigator Grant (CSASI21jun-003) and the Pangestu Family Foundation Gynaecological Cancer Research Fund (recipient: D.S.T.). Yonsei University provided the study sponsorship. The drug provider or funding source was not involved in the study design, data collection, analysis, or manuscript writing. We appreciate all the patients, their families, and all the contributors at each participating site. We would like to thank Petar Jelinic, Sarper Toker, and Soo Yeon Ihm from the MSD for helping to initiate this investigator-initiated trial. Collaborators who helped enroll patients for this study were Sunghoon Kim and Yong Jae Lee from Severance Hospital, Mi-Kyung Kim from Ewha Womans University Mokdong Hospital, Taek Sang Lee from Seoul National University Boramae Medical Center, Won Kyo Shin and Heon Jong Yoo from Choong Name Sejong Hospital, Kyung Jin Min from Korea University Ansan Hospital, Hyun Woon Cho from Korea University Kuro Hospital, and Sook-Hee Hong from Seoul Saint Mary’s Hospital, the Catholic University of Korea. We would also like to acknowledge Eun Hae Cho from GC Genome and Jung Kyoon Choi from KAIST, who assisted with the biomarker study.